Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Potent, selective PDE5 inhibitors prepared and tested at Lilly Icos

Jan. 22, 2003

Long-term effects of tranilast in oligoasthenozoospermia

Jan. 20, 2003

Possible explanation for sildenafil-associated thrombotic conditions

Jan. 20, 2003

ARYx reports new anticholinergics with utility in urinary incontinence and COPD

Jan. 20, 2003

GSK launches Avodart for BPH in U.S.

Jan. 16, 2003

Collegium enters antibody licensing agreement with Tufts for HUS

Jan. 15, 2003

Possible treatment for IgA nephropathy being developed by CuraGen and Abgenix

Jan. 14, 2003

Muscarinic receptor antagonist with better selectivity for bladder over salivation than tolterodine

Jan. 13, 2003

Yamanouchi submits NDA for YM-905 to treat overactive bladder

Jan. 13, 2003

Phase II study of RTX in interstitial cystitis commences

Jan. 13, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...